BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32454905)

  • 1. The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA.
    Shen C; Liu J; Wang J; Yang X; Niu H; Wang Y
    Dis Markers; 2020; 2020():4312629. PubMed ID: 32454905
    [No Abstract]   [Full Text] [Related]  

  • 2. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
    Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
    Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant promoter 2 methylation‑mediated downregulation of protein tyrosine phosphatase, non‑receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
    Liu L; Zhang S; Liu X; Liu J
    Mol Med Rep; 2019 Apr; 19(4):3273-3282. PubMed ID: 30816454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
    Lv J; Zhu Y; Ji A; Zhang Q; Liao G
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer.
    Zhang Q; Liu Y; Chen P; Shi X; Liu Y; Shi L; Cong P; Mao S; Tong C; Du C; Hou M
    Bioengineered; 2021 Dec; 12(1):4946-4961. PubMed ID: 34365894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico analysis of the immune microenvironment in bladder cancer.
    Zhang Y; Ou DH; Zhuang DW; Zheng ZF; Lin ME
    BMC Cancer; 2020 Mar; 20(1):265. PubMed ID: 32228629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer.
    Li F; Guo H; Wang Y; Liu B; Zhou H
    Int Immunopharmacol; 2020 Aug; 85():106641. PubMed ID: 32470882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis.
    Zhu YD; Lu MY
    Mol Med Rep; 2018 Sep; 18(3):3403-3410. PubMed ID: 30066919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
    Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
    Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
    Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
    Front Immunol; 2019; 10():6. PubMed ID: 30761122
    [No Abstract]   [Full Text] [Related]  

  • 12. Opa interacting protein 5 acts as an oncogene in bladder cancer.
    He X; Hou J; Ping J; Wen D; He J
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2221-2233. PubMed ID: 28752236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor‑infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
    Xue Y; Tong L; LiuAnwei Liu F; Liu A; Zeng S; Xiong Q; Yang Z; He X; Sun Y; Xu C
    Oncol Rep; 2019 Aug; 42(2):581-594. PubMed ID: 31233191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer.
    Shi S; Ye S; Mao J; Ru Y; Lu Y; Wu X; Xu M; Zhu T; Wang Y; Chen Y; Tang X; Xi Y
    Autoimmunity; 2020 Jun; 53(4):210-217. PubMed ID: 32129682
    [No Abstract]   [Full Text] [Related]  

  • 15. Upregulation of CEP55 Predicts Dismal Prognosis in Patients with Liver Cancer.
    Yang L; He Y; Zhang Z; Wang W
    Biomed Res Int; 2020; 2020():4139320. PubMed ID: 32337246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immunogenic cell death-related lncRNA signature correlates with prognosis and tumor immune microenvironment in bladder cancer.
    Luo J; Luo F; Li Q; Liu Q; Wang J
    Sci Rep; 2024 Jun; 14(1):13106. PubMed ID: 38849410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High expression of activated CD4
    Li W; Zeng J; Luo B; Mao Y; Liang Y; Zhao W; Hu N; Chen G; Zheng X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Feb; 36(2):97-103. PubMed ID: 32314705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of KLRB1 and its further association with immune cells in breast cancer.
    Xu N; Meng X; Chu H; Yang Z; Jiao Y; Li Y
    PeerJ; 2023; 11():e15654. PubMed ID: 37520246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.
    Sooman L; Ekman S; Tsakonas G; Jaiswal A; Navani S; Edqvist PH; Pontén F; Bergström S; Johansson M; Wu X; Blomquist E; Bergqvist M; Gullbo J; Lennartsson J
    Tumour Biol; 2014 May; 35(5):4479-88. PubMed ID: 24510345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.